Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.41 EUR | +8.28% | +2.58% | +35.90% |
Feb. 06 | Transcript : Apontis Pharma AG - Special Call | |
Nov. 09 | Apontis Pharma Provides Earnings Guidance for the Full Year 2023 | CI |
Sales 2023 * | 36.23M 39.16M | Sales 2024 * | 40.53M 43.8M | Capitalization | 51.65M 55.81M |
---|---|---|---|---|---|
Net income 2023 * | -14M -15.13M | Net income 2024 * | -2M -2.16M | EV / Sales 2023 * | 1.04 x |
Net cash position 2023 * | 13.93M 15.06M | Net cash position 2024 * | 4.93M 5.33M | EV / Sales 2024 * | 1.15 x |
P/E ratio 2023 * |
-3.56
x | P/E ratio 2024 * |
-24.5
x | Employees | 168 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 98% |
Latest transcript on Apontis Pharma AG
1 day | +8.28% | ||
1 week | +2.58% | ||
Current month | +4.61% | ||
1 month | +8.53% | ||
3 months | +39.47% | ||
6 months | +52.52% | ||
Current year | +35.90% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 57 | - | |
Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
Chairman | 50 | 20-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 6.36 | +7.43% | 0 |
24-03-27 | 5.92 | +0.34% | 0 |
24-03-26 | 5.9 | -3.59% | 600 |
24-03-25 | 6.12 | -2.55% | 0 |
24-03-22 | 6.28 | +1.29% | 0 |
Delayed Quote Deutsche Boerse AG, March 28, 2024 at 04:37 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+1.02% | 210B | |
+2.47% | 210B | |
-6.58% | 201B | |
-3.51% | 157B |
- Stock
- Equities
- Stock Apontis Pharma AG
- Stock Apontis Pharma AG - Deutsche Boerse AG